L3VLUP
ProSign in

FDMT · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

FDMTAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • FDMT
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterFDMTAMGN
Q3 2020none listed holders, n.a.16 holders, $16.3bn
Q4 20204 holders, $172m19 holders, $14.0bn
Q1 20212 holders, $175m16 holders, $14.5bn
Q2 20212 holders, $96m23 holders, $13.8bn
Q3 20212 holders, $109m24 holders, $11.6bn
Q4 20212 holders, $89m21 holders, $10.4bn
Q1 20221 holders, $60m23 holders, $9.9bn
Q2 20221 holders, $27m28 holders, $9.7bn
Q3 20221 holders, $32m21 holders, $7.9bn
Q4 20223 holders, $120m24 holders, $9.3bn
Q1 20232 holders, $100m22 holders, $8.4bn
Q2 20232 holders, $138m26 holders, $7.4bn
Q3 20232 holders, $96m26 holders, $8.7bn
Q4 20232 holders, $160m24 holders, $8.4bn
Q1 20245 holders, $211m25 holders, $6.7bn
Q2 20243 holders, $130m20 holders, $8.0bn
Q3 20241 holders, $34m21 holders, $8.8bn
Q4 2024none listed holders, n.a.20 holders, $8.2bn
Q1 2025none listed holders, n.a.25 holders, $12.0bn
Q2 2025none listed holders, n.a.20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 20251 holders, $35m19 holders, $18.0bn
Q1 20261 holders, $49m15 holders, $21.4bn
Q2 20261 holders, $76m23 holders, $24.9bn
FDMT

4D Molecular Therapeutics In

Holders
1
Reported value
$49m
Buyers
8
Sellers
15

Breadth -7 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
15
Reported value
$21.4bn
Buyers
17
Sellers
15

Breadth +2 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2026

Among the 15 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only FDMT (0)

None.

Only AMGN (14)

AllianceBernstein LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →